BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from offering solely Lapiplasty, its leading technology ...

2025 Outlook Treace plans to provide 2025 financial guidance during its fourth quarter 2024 earnings conference call, which is currently scheduled for Thursday, February 27, 2025, at 4:30 p.m ...

(RTTNews) - Treace Medical Concepts, Inc. (TMCI), a leading innovator in medical technologies for bunion and midfoot deformity treatment, announced on Tuesday the successful completion of its ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company ...